MA27868A1 - Peptides pour le traitement du cancer associe au virus du papillome humain (vph) et d'autres tumeurs. - Google Patents

Peptides pour le traitement du cancer associe au virus du papillome humain (vph) et d'autres tumeurs.

Info

Publication number
MA27868A1
MA27868A1 MA27740A MA27740A MA27868A1 MA 27868 A1 MA27868 A1 MA 27868A1 MA 27740 A MA27740 A MA 27740A MA 27740 A MA27740 A MA 27740A MA 27868 A1 MA27868 A1 MA 27868A1
Authority
MA
Morocco
Prior art keywords
peptides
hpv
tumors
treatment
papilloma virus
Prior art date
Application number
MA27740A
Other languages
English (en)
Inventor
Rodriguez Silvio Ernesto Perea
Acosta Osvaldo Reyes
Vispo Nelson Francisc Santiago
Izaguirre Yaquelin Puchades
Rodriguez Ricardo Silva
Soria Alejandro Moro
Savio Alicia Santos
Lopez Luis Javier Gonzalez
Barrios Belkis Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MA27868A1 publication Critical patent/MA27868A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des peptides utilisés pour le traitement de tumeurs d'origine épithéliale, et spécifiquement de ceux associés à des types oncogènes du virus du papillome (VPH). L'invention se rapporte également à l'identification de peptides dont la structure permet le blocage du domaine de phosphorilation par la caséine kinase II (CKII) par le biais de l'interaction directe avec ledit site. Dans la présente invention, on travaille sur onze peptides à structure cyclique et séquence d'acides aminés différentes, lesquels inhibent le site de phosphorilation par CKII in vitro, produisent une cytotoxicité dans les cellules de carcinome du col utérin humain transformées par VPH-16 (CaSki) et augmentent par ailleurs la sensibilité desdites cellules à l'action cytostatique de l'interféron (IFN). L'invention se rapporte de plus à l'usage de ces peptides conjugués ou fusionnés avec d'autres peptides et composés chimiques à pénétration intracellulaire et à l'utilisation de molécules mimétiques d'origine peptidique et chimique.
MA27740A 2001-12-20 2004-06-15 Peptides pour le traitement du cancer associe au virus du papillome humain (vph) et d'autres tumeurs. MA27868A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010309A CU23225A1 (es) 2001-12-20 2001-12-20 PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Publications (1)

Publication Number Publication Date
MA27868A1 true MA27868A1 (fr) 2006-05-02

Family

ID=40091679

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27740A MA27868A1 (fr) 2001-12-20 2004-06-15 Peptides pour le traitement du cancer associe au virus du papillome humain (vph) et d'autres tumeurs.

Country Status (34)

Country Link
US (2) US7374767B2 (fr)
EP (2) EP1491553B1 (fr)
JP (1) JP4056476B2 (fr)
KR (1) KR100642437B1 (fr)
CN (1) CN100368431C (fr)
AR (1) AR037825A1 (fr)
AT (1) ATE520704T1 (fr)
AU (1) AU2002361922B2 (fr)
BR (1) BRPI0215213C1 (fr)
CA (1) CA2471110C (fr)
CR (1) CR7361A (fr)
CU (1) CU23225A1 (fr)
DK (1) DK1491553T3 (fr)
DO (1) DOP2002000548A (fr)
ES (1) ES2371239T3 (fr)
HK (1) HK1068901A1 (fr)
HN (1) HN2002000377A (fr)
HR (1) HRP20040663B1 (fr)
IL (2) IL162633A0 (fr)
IS (1) IS2906B (fr)
MA (1) MA27868A1 (fr)
MX (1) MXPA04005832A (fr)
MY (1) MY133530A (fr)
NO (1) NO333259B1 (fr)
NZ (1) NZ534170A (fr)
PE (1) PE20030861A1 (fr)
PT (1) PT1491553E (fr)
RU (1) RU2290410C2 (fr)
SI (1) SI1491553T1 (fr)
TN (1) TNSN04114A1 (fr)
UA (1) UA81403C2 (fr)
UY (1) UY27602A1 (fr)
WO (1) WO2003054002A1 (fr)
ZA (1) ZA200405514B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB2441131A (en) * 2006-08-24 2008-02-27 Univ Dundee Modulation of binding of CK2a to NDPK
CN100522992C (zh) * 2007-02-12 2009-08-05 中国科学院昆明动物研究所 一种环状小肽ba
CN101641104B (zh) * 2007-03-27 2013-06-05 大幸药品株式会社 感染性皮肤和粘膜疾病治疗药
WO2010096751A1 (fr) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions et méthodes de traitement d'une maladie médiée par le bêta-amyloïde oligomère soluble
EP2406379A4 (fr) * 2009-03-13 2012-09-26 Egen Inc Compositions et procédés pour l'administration d'arn biologiquement actifs
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CU20210058A7 (es) 2021-07-09 2023-02-13 Ct Ingenieria Genetica Biotecnologia Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902820A1 (en) * 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
CA2077322A1 (fr) * 1991-09-04 1993-03-05 Allen I. Oliff Peptides inhibant la liaison de la proteine du papillomavirus humain avec les proteines codees par le gene du retinoblastome
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
ATE235509T1 (de) * 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
AU2001238347A1 (en) * 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Also Published As

Publication number Publication date
DOP2002000548A (es) 2003-06-30
HRP20040663A2 (en) 2005-08-31
MXPA04005832A (es) 2004-09-13
US20060233742A1 (en) 2006-10-19
CN1620464A (zh) 2005-05-25
IL162633A (en) 2011-02-28
BR0215213A (pt) 2004-12-07
AR037825A1 (es) 2004-12-09
KR100642437B1 (ko) 2006-11-06
ES2371239T3 (es) 2011-12-28
US7374767B2 (en) 2008-05-20
KR20050002811A (ko) 2005-01-10
DK1491553T3 (da) 2011-12-05
BRPI0215213C1 (pt) 2021-05-25
MY133530A (en) 2007-11-30
ATE520704T1 (de) 2011-09-15
HRP20040663B1 (hr) 2013-05-31
EP1491553A1 (fr) 2004-12-29
CU23225A1 (es) 2007-08-30
CA2471110A1 (fr) 2003-07-03
RU2004122084A (ru) 2005-03-27
BRPI0215213B1 (pt) 2018-09-11
US7947287B2 (en) 2011-05-24
JP2005525090A (ja) 2005-08-25
HK1068901A1 (en) 2005-05-06
IS7320A (is) 2004-06-16
EP1491553B1 (fr) 2011-08-17
PT1491553E (pt) 2011-11-25
SI1491553T1 (sl) 2011-12-30
UA81403C2 (en) 2008-01-10
NO20043112L (no) 2004-07-20
AU2002361922A1 (en) 2003-07-09
NZ534170A (en) 2006-08-31
UY27602A1 (es) 2003-04-30
AU2002361922B2 (en) 2007-04-05
IL162633A0 (fr) 2005-11-20
RU2290410C2 (ru) 2006-12-27
IS2906B (is) 2014-11-15
EP2383282A1 (fr) 2011-11-02
CR7361A (es) 2005-02-18
ZA200405514B (en) 2005-03-30
PE20030861A1 (es) 2003-12-02
JP4056476B2 (ja) 2008-03-05
CN100368431C (zh) 2008-02-13
HN2002000377A (es) 2003-04-10
WO2003054002A1 (fr) 2003-07-03
CA2471110C (fr) 2017-01-31
NO333259B1 (no) 2013-04-22
US20090005294A1 (en) 2009-01-01
TNSN04114A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
MA27868A1 (fr) Peptides pour le traitement du cancer associe au virus du papillome humain (vph) et d'autres tumeurs.
CA2094705A1 (fr) Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne
RU2018100181A (ru) Модифицированный белок интерлейкина-7 и способы его применения
AU2017385913B2 (en) Pharmaceutical composition comprising F1 and F3 polypeptides, and application thereof in treating HPV infection
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
EA200401064A1 (ru) Вирусоподобные частицы из вируса папилломы человека
EA200200820A1 (ru) Пептиды, полученные из казеина, и их применение в терапии
DE69330988D1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
CA2699894A1 (fr) Derives de cholesterol d'inhibiteurs de la fusion virale
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
EA200000144A1 (ru) Направленный цитолиз клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, которые можно использовать для получения этих агентов
CA2098819A1 (fr) Sequences d'adn derivees du genome du papillomavirus hpv39, leur application au diagnostic in vitro et a la production de composition immunogene
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
CN116801908A (zh) 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法
BR0111393A (pt) Métodos de tratamento de doenças virais com il-18 e suas combinações
ATE356207T1 (de) Humanes btrcp protein
HK1046535B (zh) 人類內生性逆轉濾過性病毒
ATE300943T1 (de) Therapeutische quassinoid-zubereitungen mit antineoplastischer, antiviraler und herbistatischer wirkung
DE50002164D1 (de) Peptide zur inhibierung von hpv e6-proteinen
CY1112340T1 (el) Πεπτιδια για την θεραπευτικη αγωγη καρκινου που συνδεεται με τον ιο ανθρωπινων θηλωματων (hpv) και αλλων επιθηλιακων ογκων
TH59183B (th) เพพไทด์สำหรับการรักษามะเร็งที่เกี่ยวข้องกับแพพิลโลมาไวรัส (hpv) ของมนุษย์และเนื้องอกของเนื้อเยื่อบุผิวอื่น
TH62586A (th) เพพไทด์สำหรับการรักษามะเร็งที่เกี่ยวข้องกับแพพิลโลมาไวรัส (hpv) ของมนุษย์และเนื้องอกของเนื้อเยื่อบุผิวอื่น
RU2008152813A (ru) Пептиды с антипролиферативной активностью
TH7280EX (th) เพปไทด์ที่เป็นแอนติเจนของไวรัสโรคตับอักเสบชนิดnon-A,non-B
WO2001034095A8 (fr) Procede pour traiter des maladies virales et d'autres troubles par la modification de l'expression genique immediate au moyen de l'administration du peptide t